# US 2010/0166799 A1 · Adenoviral vectors and methods and uses related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166799 A1
- Document ID: US20100166799A1
- Status: Published application
- Kind: A1
- Application number: 12/643,140
- Filed: 2009-12-21
- Published: 2010-07-01
- Earliest claimed: 2008-12-22
- Assignees: Oncos Therapeutics Oy
- Inventors: Akseli HEMMINKI; Anna KANERVA; Vincenzo CERULLO; Sari PESONEN
- Web page: https://patentgrep.com/patent/US20100166799A1

## CPC

- C12N 15/86: Viral vectors
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/04: specific for metastasis
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C12N 2710/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10352: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2710/10371: Demonstrated in vivo effect
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject.

## Claims

### Claim 1

An oncolytic adenoviral vector, comprising:
an adenovirus serotype 5 (Ad5) nucleic acid backbone; a 24 bp deletion (D24) in the Rb binding constant region 2 of E1; and
a nucleic acid sequence encoding a granulocyte-macrophage colony-stimulating factor (GM-CSF) in the place of the deleted gp19k/6.7K in the E3 region.

### Claim 2 (depends on 1)

The oncolytic adenoviral vector according to claim 1, further comprising one or more regions selected from a group consisting of E2, E4, and late regions.

### Claim 3 (depends on 1)

The oncolytic adenoviral vector according to claim 1, comprising the following regions: a left ITR, partial E1, pIX, pIVa2, E2, VA1, VA2, L1, L2, L3, L4, partial E3, L5, E4, and a right ITR.

### Claim 4 (depends on 3)

The oncolytic adenoviral vector according to claim 3, wherein the regions are in a sequential order in the 5′ to 3′ direction.

### Claim 5 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein a wild type region is located upstream of the E1 region.

### Claim 6 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein the E1 region comprises a viral packaging signal.

### Claim 7 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein a nucleic acid sequence encoding GM-CSF is under the control of the viral E3 promoter.

### Claim 8 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein a nucleic acid sequence encoding GM-CSF is of a wild type.

### Claim 9 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein the E4 region is of a wild type.

### Claim 10 (depends on 1)

The oncolytic adenoviral vector according to claim 1, further comprising a capsid modification.

### Claim 11 (depends on 10)

The oncolytic adenoviral vector according to claim 10, wherein the capsid modification is Ad5/3 chimerism, insertion of an integrin binding (RGD) region and/or heparin sulphate binding polylysine modification into the fiber.

### Claim 12 (depends on 10)

The oncolytic adenoviral vector according to claim 10, wherein the capsid modification is a RGD-4C modification.

### Claim 13 (depends on 1)

The oncolytic adenoviral vector according to claim 1, further comprising at least one expression cassette.

### Claim 14 (depends on 1)

The oncolytic adenoviral vector according to claim 1, further comprising only one expression cassette.

### Claim 15 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein the vector is capable of selectively replicating in cells having defects in the Rb-pathway.

### Claim 16 (depends on 1)

A cell comprising the adenoviral vector according to claim 1.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the adenoviral vector according to claim 1.

### Claim 18 (depends on 1)

An oncolytic adenoviral vector according to claim 1, which acts as an in situ cancer vaccine.

### Claim 19 (depends on 1)

A method of treating cancer in a subject in need thereof, comprising:
administering an effective amount of the adenoviral vector according to claim 1 to the subject in a subject.

### Claim 20 (depends on 17)

A method of treating cancer in a subject in need thereof, comprising:
administering the pharmaceutical composition according to claim 17 to the subject.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the cancer is selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer, tonsil cancer.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the subject is a human or an animal.

### Claim 23 (depends on 20)

The method according to claim 20, wherein the administration is conducted through an intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary or peritoneal injection, or an oral administration.

### Claim 24 (depends on 20)

The method according to claim 20, wherein the pharmaceutical composition is administered several times during the treatment period.

### Claim 25 (depends on 19)

The method according to claim 19, wherein the oncolytic adenoviral vector having a different fiber knob of the capsid compared to the vector of the earlier treatment, is administered to the subject.

### Claim 26 (depends on 20)

The usc or method according to claim 20, further comprising administering concurrent radiotherapy to the subject.

### Claim 27 (depends on 20)

The method according to claim 20, further comprising administering concurrent chemotherapy to the subject.

### Claim 28 (depends on 20)

The usc or method according to claim 20, further comprising administering verapamil or another calcium channel blocker to the subject.

### Claim 29 (depends on 20)

The method according to claim 20, further comprising administering autophagy inducing agents to the subject.

### Claim 30 (depends on 20)

The method according to claim 20, further comprising administering temozolomide to the subject.

### Claim 31 (depends on 20)

The method according to claim 20, further comprising administering administration of chemotherapy or anti-CD20 therapy or other approaches for blocking of neutralizing antibodies.

### Claim 32 (depends on 20)

The method according to claim 20, further comprising administering substances capable to downregulating regulatory T-cells in the subject.

### Claim 33 (depends on 20)

The usc or method according to claim 20, further comprising administering of cyclophosphamide to the subject.

### Claim 34 (depends on 1)

A method of producing GM-CSF in a cell, comprising:
a) carrying a vehicle comprising the oncolytic adenoviral vector according to claim 1 to a cell, and
b) expressing GM-CSF of the vector in the cell.

### Claim 35 (depends on 1)

A method of increasing tumor specific immune response in a subject, comprising:
a) carrying a vehicle comprising the oncolytic adenoviral vector according to claim 1 to a target cell or tissue,
b) expressing GM-CSF of the vector in the cell, and
c) increasing amount of cytotoxic T cells and/or natural killer cells in the target cell or tissue.

### Claim 36 (depends on 1)

A method for producing GM-CSF in a cell, comprising:
administering the oncolytic adenoviral vector according to claim 1.

### Claim 37 (depends on 1)

A method for increasing tumor specific immune response in a subject, comprising:
administering the oncolytic adenoviral vector according to claim 1.

### Claim 38 (depends on 37)

The method according to claim 37, wherein an amount of natural killer and/or cytotoxic T cells is increased in a target cell or tissue.

### Claim 39 (depends on 17)

A pharmaceutical composition according to claim 17, which acts as an in situ cancer vaccine.

### Claim 40 (depends on 19)

The method according to claim 19, wherein the cancer is selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer, tonsil cancer.

### Claim 41 (depends on 19)

The method according to claim 19, wherein the subject is a human or an animal.

### Claim 42 (depends on 19)

The method according to claim 19, wherein administering comprises intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary, peritoneal injection, or oral administration.

### Claim 43 (depends on 19)

The method according to claim 19, wherein the oncolytic adenoviral vector is administered several times during the treatment period.

### Claim 44 (depends on 19)

The method according to claim 19, further comprising administering of concurrent radiotherapy to the subject.

### Claim 45 (depends on 19)

The method according to claim 19, further comprising administering concurrent chemotherapy to the subject.

### Claim 46 (depends on 19)

The method according to claim 19, further comprising administering verapamil or another calcium channel blocker to the subject.

### Claim 47 (depends on 19)

The method according to claim 19, further comprising administering autophagy inducing agents to the subject.

### Claim 48 (depends on 19)

The method according to claim 19, further comprising administering temozolomide to the subject.

### Claim 49 (depends on 19)

The method according to claim 19, further comprising administering chemotherapy or anti-CD20 therapy or other approaches for blocking of neutralizing antibodies.

### Claim 50 (depends on 19)

The method according to claim 19, further comprising administering substances capable of downregulating regulatory T-cells in a subject.

### Claim 51 (depends on 19)

The method according to claim 19, further comprising administering cyclophosphamide to the subject.
